Screening for Lung Cancer in Subjects With Family History of Lung Cancer

Sponsor
The University of Hong Kong (Other)
Overall Status
Recruiting
CT.gov ID
NCT05762731
Collaborator
The Queen Elizabeth Hospital (Other), Kwong Wah Hospital (Other), Hong Kong Sanatorium & Hospital (Industry)
1,520
1
34
44.7

Study Details

Study Description

Brief Summary

Lung cancer can be detected via screening of high-risk individuals, i.e current or ex-heavy smokers, with low-dose computer tomography (LDCT) of thorax. The National Lung Screening Trial in US and the NELSON trial in Europe demonstrated reduction in lung cancer mortality with LDCT screening for lung cancer. In Hong Kong, however, there is a prominence of female never-smokers with lung cancer. There is no identifiable risk factors for non-smokers with lung cancer except family history of lung cancer. The hypothesis is that lung cancer screening for subjects with family history of lung cancer, can detect early lung cancer.

Condition or Disease Intervention/Treatment Phase
  • Diagnostic Test: Low dose CT thorax
  • Diagnostic Test: Low dose CT thorax

Detailed Description

The primary aim of this prospective study is to find out the rate of lung cancer detection in subjects who are first degree relatives of lung cancer patients. Secondary aims include studying the characteristics of screen-detected lung cancer. This is a multi-centered prospective cohort study. 1,520 subjects who are first degree relatives of lung cancer patients at four public hospitals in Hong Kong will be screened. Intervention Detailed questionnaires and LDCT Thorax will be performed. The primary outcome measure is the number of lung cancers detected by this study. The screening-detection rate of lung cancer in first-degree relatives of lung cancer patients will be estimated.

Study Design

Study Type:
Observational [Patient Registry]
Anticipated Enrollment :
1520 participants
Observational Model:
Case-Control
Time Perspective:
Prospective
Official Title:
Screening for Lung Cancer in Subjects With Family History of Lung Cancer
Actual Study Start Date :
Feb 1, 2023
Anticipated Primary Completion Date :
Dec 1, 2024
Anticipated Study Completion Date :
Dec 1, 2025

Arms and Interventions

Arm Intervention/Treatment
First degree relatives of lung cancer patients

Age 50-75, men or women, smokers or non-smokers. Being first degree relatives (siblings, children and parents) of lung cancer subjects. Having no known lung cancer before.

Diagnostic Test: Low dose CT thorax
A multi-detector row CT scanner with minimum section collimation of ≤1 mm and minimum number of data acquisition channels ≥ 16will be employed.

Control group

Non-lung cancer subjects who are not related any lung cancer patients

Diagnostic Test: Low dose CT thorax
Control subjects will also proceed to CT thorax, and outcome measures be compared to subjects

Outcome Measures

Primary Outcome Measures

  1. The rate of lung cancer detection in subjects with family history of lung cancer [An average of 2.5 years]

    The number of screening-detected lung cancer among first degree relatives of lung cancer patients.

Secondary Outcome Measures

  1. The characteristics of screening detected lung cancer [An average of 2.5 years]

    Stage distribution of lung cancer detected.

Eligibility Criteria

Criteria

Ages Eligible for Study:
50 Years to 75 Years
Sexes Eligible for Study:
All
Inclusion Criteria:
  • Age 50-75, men or women, smokers or non-smokers

  • Being first degree relatives (Siblings, children, and parents) of lung cancer subjects

  • Having no known lung cancer before

Exclusion Criteria:
  • Non-Chinese

  • Mentally incompetent to give informed consent

Contacts and Locations

Locations

Site City State Country Postal Code
1 University of Hong Kong Hong Kong Hong Kong 0

Sponsors and Collaborators

  • The University of Hong Kong
  • The Queen Elizabeth Hospital
  • Kwong Wah Hospital
  • Hong Kong Sanatorium & Hospital

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Additional Information:

Publications

Responsible Party:
The University of Hong Kong
ClinicalTrials.gov Identifier:
NCT05762731
Other Study ID Numbers:
  • HKU_UW_19_444
First Posted:
Mar 10, 2023
Last Update Posted:
Mar 10, 2023
Last Verified:
Jan 1, 2023
Individual Participant Data (IPD) Sharing Statement:
Undecided
Plan to Share IPD:
Undecided
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by The University of Hong Kong
Additional relevant MeSH terms:

Study Results

No Results Posted as of Mar 10, 2023